The Only Industry-Specific Event for
Respiratory Drug Developers
Reimagine Clinical Trial Design, Harness Patient Phenotyping, Explore Innovative Therapeutic Modalities, & Learn New Mechanisms of Action to Transform ARDS Drug Development
Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2023 event, please get in touch at info@hansonwade.com
Navigate clinical trial design to meet both early and late-stage endpoints, discover therapeutic opportunities with patient biomarkers and phenotyping, and uncover the latest clinical trial advancements to benchmark your therapeutic modality, at the 2nd ARDS Drug Development Summit. This is the only translational conference for drug developers to learn from and move past the clinical trial setbacks.
Developed exclusively to define and advance the therapeutic opportunity and consolidate translational data in ARDS, join over 100+ inflammation and respiratory experts including Mesoblast, Healios, Biomarck Pharmaceuticals, Edesa Biotech, Tetra Biopharma, Apeptico, Aptarion Biotech, and many more.
Don't miss this unique opportunity to deep dive into the hottest ARDS research, ensuring your team gains actionable insights to supercharge your drug development and bring life-changing therapies for ARDS patients around the world.
60+
Experienced Attendees
20+
Expert
Speakers
15+
Dedicated Sessions
2
Interactive Workshops
3
Unmissable Days
2022 World Class Speaker Faculty Included:
Alistair Wheeler
Chief Medical Officer
BioMarck Pharmaceuticals
Silviu Itescu
Chief Executive Officer
Mesoblast
Axel Vater
Founder & Chief Scientific Officer
Aptarion Biotech
Bernhard Fischer
Chief Executive Officer
Apeptico
Ritu Lal
Chief Executive Officer
Gen1E Lifesciences
B. Taylor Thompson
Professor of Medicine
Massachusetts General Hospital
Harvard Medical School
Why Does the Industry Want to Attend?
Other Events in the Series
